Gynecologic Cancers | Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Michael J Birrer, Ursula Matulonis, David M O’Malley and Krishnansu S Tewari. Molecular subtypes of endometrial cancer and response to immune checkpoint inhibitors; testing for mismatch repair deficiency and POLE mutations (00:00) Integration of immune checkpoint inhibitors into the management of endometrial cancer (10:31) Efficacy and tolerability of anti-PD-1/PD-L1 antibodies for endometrial cancer; incorporation of pembrolizumab/lenvatinib into the treatment algorithm (17:24) Activity of immune checkpoint inhibitors alone and in combination with chemotherapy for cervical cancer; results from the JAVELIN Ovarian 100 trial evaluating avelumab as first-line therapy for ovarian cancer (29:16) Role of immune checkpoint inhibitors in the first- and second-line settings for patients with metastatic cervical cancer; perspective on hyperprogression and pseudoprogression (40:38) Emerging data with immune checkpoint inhibitors in combination with chemotherapy or PARP inhibitors for ovarian cancer; recent guidelines regarding mismatch repair deficiency testing (53:07) Mechanism of action, dosing and ongoing evaluation of dostarlimab for advanced or recurrent endometrial cancer (57:07) Novel antibody-drug conjugate tisotumab vedotin under investigation for gynecologic cancers (1:02:55) Side effects associated with tisotumab vedotin (1:09:56) Challenges with immunotherapy for patients with gynecologic cancers in the COVID-19 era (1:16:20) Impact of COVID-19 on clinical research for patients with gynecologic cancers (1:22:13) CME information and select publications